Show simple item record

dc.contributor.authorSaygin, Z.M.
dc.contributor.authorKliemann, D.
dc.contributor.authorIglesias, J.E.
dc.contributor.authorvan der Kouwe, A.J.W.
dc.contributor.authorBoyd, E.
dc.contributor.authorReuter, M.
dc.contributor.authorStevens, A.
dc.contributor.authorVan Leemput, K.
dc.contributor.authorMcKee, A.
dc.contributor.authorFrosch, M.P.
dc.contributor.authorFischl, B.
dc.contributor.authorAugustinack, J.C.
dc.contributor.authorfor the Alzheimer's Disease Neuroimaging Initiative
dc.date.accessioned2017-11-24T15:03:17Z
dc.date.available2017-11-24T15:03:17Z
dc.date.issued2017
dc.identifier.citationZ.M. Saygin, D. Kliemann, J.E. Iglesias, A.J.W. van der Kouwe, E. Boyd, M. Reuter, A. Stevens, K. Van Leemput, A. McKee, M.P. Frosch, B. Fischl, J.C. Augustinack, High-resolution magnetic resonance imaging reveals nuclei of the human amygdala: manual segmentation to automatic atlas, In NeuroImage, Volume 155, 2017, Pages 370-382, ISSN 1053-8119, https://doi.org/10.1016/j.neuroimage.2017.04.046.es_ES
dc.identifier.issn1053-8119
dc.identifier.urihttp://hdl.handle.net/10810/23715
dc.descriptionAvailable online 4 May 2017es_ES
dc.description.abstractThe amygdala is composed of multiple nuclei with unique functions and connections in the limbic system and to the rest of the brain. However, standard in vivo neuroimaging tools to automatically delineate the amygdala into its multiple nuclei are still rare. By scanning postmortem specimens at high resolution (100–150 µm) at 7 T field strength (n = 10), we were able to visualize and label nine amygdala nuclei (anterior amygdaloid, cortico-amygdaloid transition area; basal, lateral, accessory basal, central, cortical medial, paralaminar nuclei). We created an atlas from these labels using a recently developed atlas building algorithm based on Bayesian inference. This atlas, which will be released as part of FreeSurfer, can be used to automatically segment nine amygdala nuclei from a standard resolution structural MR image. We applied this atlas to two publicly available datasets (ADNI and ABIDE) with standard resolution T1 data, used individual volumetric data of the amygdala nuclei as the measure and found that our atlas i) discriminates between Alzheimer's disease participants and age-matched control participants with 84% accuracy (AUC=0.915), and ii) discriminates between individuals with autism and age-, sex- and IQ-matched neurotypically developed control participants with 59.5% accuracy (AUC=0.59). For both datasets, the new ex vivo atlas significantly outperformed (all p < .05) estimations of the whole amygdala derived from the segmentation in FreeSurfer 5.1 (ADNI: 75%, ABIDE: 54% accuracy), as well as classification based on whole amygdala volume (using the sum of all amygdala nuclei volumes; ADNI: 81%, ABIDE: 55% accuracy). This new atlas and the segmentation tools that utilize it will provide neuroimaging researchers with the ability to explore the function and connectivity of the human amygdala nuclei with unprecedented detail in healthy adults as well as those with neurodevelopmental and neurodegenerative disorders.es_ES
dc.description.sponsorshipThis work was supported by the PHS grant DA023427 and NICHD/ NIH grant F32HD079169 (Z.M.S); Feodor Lynen Postdoctoral Fellowship of the Alexander von Humboldt Foundation (D.K.); R21(MH106796), R21 (AG046657) and K01AG28521 (J.C.A.), the National Cancer Institute (1K25CA181632-01) as well as the Genentech Foundation (M.R.); the European Union's Horizon 2020 Marie Sklodowska-Curie grant agreement No 654911 (project ”THALAMODEL”) and ERC Starting Grant agreement No 677697 (project “BUNGEE-TOOLS”); and the Spanish Ministry of Economy and Competitiveness (MINECO) reference TEC2014-51882-P (J.E.I.); and the NVIDIA hardware award (M.R. and J.E.I.). Further support for this research was provided in part by the National Institute for Biomedical Imaging and Bioengineering (P41EB015896, R01EB006758, R21EB018907, R01EB019956, R01- EB013565), the National Institute on Aging (5R01AG008122, R01AG016495), the National Institute of Diabetes and Digestive and Kidney Diseases (1-R21-DK-108277-01), the National Institute for Neurological Disorders and Stroke (R01NS0525851, R21NS072652, R01NS070963, R01NS083534, 5U01NS086625), the Massachusetts ADRC (P50AG005134) and was made possible by the resources provided by Shared Instrumentation Grants 1S10RR023401, 1S10RR019307, and 1S10RR023043. Additional support was provided by the NIH Blueprint for Neuroscience Research (5U01-MH093765), part of the multi-institutional Human Connectome Project. In addition, BF has a financial interest in CorticoMetrics, a company whose medical pursuits focus on brain imaging and measurement technologies. BF's interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. The collection and sharing of the ADNI MRI data used in the evaluation was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2- 0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www. fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.es_ES
dc.language.isoenges_ES
dc.publisherNeuroImagees_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/654911es_ES
dc.relationinfo:eu-repo/grantAgreement/EC/ERC/677697es_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/TEC2014-51882-Pes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectAmygdalaes_ES
dc.subjectMedial temporal lobees_ES
dc.subjectAtlases_ES
dc.subjectEx vivoes_ES
dc.subjectAutismes_ES
dc.subjectAlzheimer'ses_ES
dc.titleHigh-resolution magnetic resonance imaging reveals nuclei of the human amygdala: manual segmentation to automatic atlases_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2017 Elsevier Inc. All rights reserved.es_ES
dc.relation.publisherversionhttps://www.journals.elsevier.com/neuroimage/es_ES
dc.identifier.doi10.1016/j.neuroimage.2017.04.046


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record